Executive DecisionIn the "Executive Decision" segment, Cramer spoke with Chris Garabedian, president and CEO of Sarepta Therapeutics ( SRPT), a small biotech firm that saw its shares soar over 200% after the company announced Wednesday positive data for its muscular dystrophy drug, Eteplirsen. Cramer recommended Sarepta as a speculative stock back on Sept. 21. Garabedian said his company is very excited about today's news and the market's response to it, as well as what the data mean to patients and their families. He then showed a chart of how patients taking Eteplirsen fared against those taking a placebo over a 48-week period. The data clearly showed those patients taking the placebo saw a steady progression of the disease until they were no longer able to walk, but those taking Eteplirsen not only stabilized but actually saw improvement in weeks 36 through 48. Sarepta has now switched those taking the placebo to Eteplirsen and is studying how the drug affects people in the later stages of the disease. Garabedian explained that while the data only include Phase II results and the sample size was 12 patients, this is not uncommon for a rare disease. What matters most is how much patients improved while taking the drug. He also responded to criticisms that two patients did not respond to the drug. He said in those cases the disease had already started progressing before the drug could take hold. Garabedian said Sarepta is amenable to taking on partners to help it speed up its Eteplirsen program and expand it overseas, but the company is also preparing to continue developing the drug in-house if necessary. Cramer said results like these don't come from a paycheck, or a bank CD or even a typical stock, they only come from speculating, which is why he has always said that speculation needs to be a part of everyone's portfolio.